Saga Diagnostics
The company develops and provides ultra-sensitive, blood-based molecular residual disease (MRD) tests for cancer detection and monitoring. Its flagship Pathlight platform uses whole-genome sequencing and digital PCR to identify patient-specific structural variants for tracking circulating tumor DNA. The technology serves clinicians treating early-stage breast cancer patients and biopharma companies supporting cancer development programs.
Healthtech
Biotechnology
Diagnostics
Oncology
Funding summary
- Total raised
- €14.0M
- Funding rounds
- 2
- Exit
- acquisition
- Exit value
- €504.0M
Investors in Saga Diagnostics
Investors on record for Saga Diagnostics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Saga Diagnostics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors